SyntheMed's REPEL-CV gets Russian go-ahead
This article was originally published in Clinica
Executive Summary
The Ministry of Health of the Russian Federation has approved REPEL-CV, SyntheMed's bioresorbable adhesion barrier film, for all patients undergoing open heart surgery. The device is designed to be placed over the surface of the heart after surgery, to reduce the formation of scars, and hence prevent the heart becoming attached to the sternum or other tissues. It will be marketed in Russia by Cardiomedics, a distributor of cardiac surgery products. REPEL-CV received US FDA premarket approval in March for paediatric cardiac surgery patients (see Clinica No 1336, p 27). Iselin, New Jersey-based SyntheMed has also CE marked the film for sale in Europe for all cardiac surgery patients.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.